医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Thermo Fisher Scientific Significantly Expands R&D Capabilities in China

2013年06月26日 AM10:25
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has established the China Innovation Center in Shanghai, significantly expanding its research, development and training capabilities to support high-growth markets in the Asia-Pacific region.

Thermo Fisher has invested $9.5 million in the new China Innovation Center to support its rapidly growing R&D organization, which is expected to add 200 to 300 engineers during the next two to three years. The new facility will include a Technology Training Center to instruct up to 2,500 customers per year in the use of its industry-leading chromatography and mass spectrometry systems, among other technologies.

“China is one of our fastest-growing markets and continues to be a key contributor to our success,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The China Innovation Center builds on our well-established local presence and is an important next step as we align our product development efforts with investments in our manufacturing infrastructure.”

Coming on the heels of the company’s new Suzhou manufacturing facility, which opened in November 2012, the China Innovation Center supports product engineering, development and training to meet the specific needs of customers in China and Asia-Pacific. Thermo Fisher built the $20 million Suzhou plant to address increased demand for laboratory equipment and consumables from life sciences customers in the region.

The China Innovation Center includes more than 30,000 square feet of biology laboratories, design-verification-test and application laboratories. An additional 10,000 square feet are reserved for training, allowing for multiple training courses to be taught simultaneously.

Since entering the Chinese market three decades ago, Thermo Fisher has established a strong commercial, manufacturing, and research and development infrastructure, becoming one of the largest companies serving the life sciences market in the country. The company founded its original China Technology Center in 2010 as a research and development site for instruments and other products for Asia-Pacific markets.

Thermo Fisher’s revenue in China grew by more than 20 percent in 2012. In addition to Shanghai and Suzhou, the company has operations in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang and Xi’an, with nearly 2,300 employees in the country.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenue of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.

CONTACT

Thermo Fisher Scientific Inc.
Media Contact Information:
Ron
O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor
Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent